Venus Concept Inc. (NASDAQ:VERO) shares fell on Wednesday after the company said it will voluntarily delist from Nasdaq and end SEC reporting.The board notified Nasdaq that it plans to leave the Nasdaq Capital Market and deregister with the SEC, citing compliance costs that outweigh the benefits of staying listed.As of September 30, 2025, the company's inventories totaled $15.768 million. Cash and equivalents totaled $4.312 million.Where And When It HappensVenus Concept said it plans to file a Form 25 with ...

Core Viewpoint - Venus Concept Inc. has announced its decision to voluntarily delist its common stock from the NASDAQ Capital Market and deregister its common stock with the SEC, citing that the costs of compliance outweigh the benefits for the company and its shareholders [1][2]. Delisting and Deregistration - The company is compliant with Nasdaq listing requirements but has determined that the resources needed for SEC reporting obligations are excessive compared to the benefits [2]. - Venus Concept has notified Nasdaq of its intent to delist and deregister, planning to file a Form 25 on or about January 30, 2026, with the last trading day expected to be around February 6, 2026 [3]. - A Form 15 will be filed on or about February 9, 2026, which will suspend the company's obligation to file periodic reports with the SEC [3]. Management's Perspective - The Board of Directors believes that this decision is in the best interests of the company and its shareholders, as it will reduce compliance costs and support the execution of the company's turnaround plan [4]. - The CEO of Venus Concept emphasized the collaboration with Madryn Asset Management to position the company for long-term financial success [4]. Company Overview - Venus Concept is a global leader in medical aesthetic technology, offering a wide range of minimally invasive and non-invasive products, reaching over 60 countries [5]. - The product portfolio includes various aesthetic device platforms and hair restoration systems, supported by prominent healthcare industry investors [5].

Core Viewpoint - Venus Concept Inc. (NASDAQ:VERO) experienced a significant stock price increase of over 500% on Friday, driven by high trading volume and strategic investment developments [1]. Group 1: Stock Performance - Venus Concept stock surged 593.01% to $9.91 at publication, with a trading volume of 223.09 million shares compared to an average volume of 1.74 million [1][6]. Group 2: Major Stake Acquisition - Madryn Asset Management disclosed a 91% stake in Venus Concept, indicating the investment is for strategic purposes [2]. - As a major shareholder, Madryn Asset Management plans to engage actively in operational, financial, and strategic initiatives, including evaluating potential strategic alternatives for the company [3]. Group 3: Financial Performance - Venus Concept reported third-quarter sales of $13.78 million, which fell short of the consensus estimate of $14.48 million, marking an 8% year-over-year decline and a 12% quarter-over-quarter decline, primarily due to a downturn in the Hair Restoration business [4]. Group 4: Product Development - The U.S. FDA granted 510(k) clearance to Venus Concept's Venus NOVA, a next-generation multi-application platform aimed at enhancing non-invasive treatments for various aesthetic applications [5]. - Venus NOVA features Adaptive Electrical Muscle Stimulation (EMS), Multi-Polar Radio Frequency (RF), Pulsed Electromagnetic Fields (PEMF), and Advanced VariPulse technology, providing a comprehensive solution for body contouring and skin treatments [6].

Core Viewpoint - Venus Concept Inc. reported financial results for Q3 2025, highlighting challenges in the aesthetics market but showing signs of stabilization in its Energy Based Device (EBD) business. The company is focused on long-term success through cash management and targeted investments, alongside a new product launch and ongoing strategic transactions [3][5]. Financial Results Summary - Total revenue for Q3 2025 was $13.8 million, down 8% year-over-year and down 12% quarter-over-quarter, primarily due to a decline in the Hair Restoration business [5][6]. - EBD revenues showed signs of stabilization with total sales of $9.6 million, up 2% year-over-year [5]. - GAAP net loss for Q3 2025 was $22.5 million, compared to a loss of $9.3 million in Q3 2024. Adjusted EBITDA loss was $7.8 million, compared to a loss of $5.9 million in the prior year [5][11]. Revenue Breakdown - U.S. revenue decreased by $1.1 million, or 12%, year-over-year, while international revenue decreased by $0.2 million, or 3% [6][7]. - Revenue by product category showed a 12% decrease in products – systems revenue, a 15% decrease in products – other revenue, and a 5% decrease in services revenue, partially offset by a 9% increase in lease systems revenue [7]. Operating Performance - Gross profit for Q3 2025 decreased by $1.1 million, or 11%, to $8.8 million, with a gross margin of 64.0%, down from 66.1% in Q3 2024 [8]. - Operating expenses increased by $1.2 million, or 7%, to $18.3 million, driven by higher general and administrative and selling and marketing expenses [9]. Strategic Developments - The company announced FDA 510(k) clearance for the Venus NOVA, its next-generation multi-application platform, marking a significant step in its R&D strategy [5]. - The company is actively pursuing the sale of its Venus Hair Business, facing challenges with the counterparty and seeking court assistance to close the transaction [3]. Balance Sheet and Cash Flow - As of September 30, 2025, the company had cash and cash equivalents of $5.9 million and total debt obligations of approximately $30.1 million, a reduction from $39.7 million at the end of 2024 [11]. - The company executed a debt-to-equity exchange transaction totaling $11.5 million, resulting in a 24% reduction in total debt compared to December 31, 2024 [5].

Core Points - Venus Concept Inc. will release its third quarter financial results for fiscal year 2025 on November 13, 2025, before market opening [1] - A conference call will be held at 8:00 a.m. Eastern Time on the same day to discuss the results and answer questions [2] - A replay of the conference call will be available for two weeks for those unable to participate live [3] Company Overview - Venus Concept is a global leader in medical aesthetic technology, offering a wide range of minimally invasive and non-invasive products [4] - The company operates in over 60 countries and has 9 direct markets, with a diverse product portfolio including various aesthetic device platforms and hair restoration systems [4] - Venus Concept is supported by prominent healthcare industry growth equity investors [4]

Company Overview - Venus Concept Inc. is a global leader in medical aesthetic technology, offering a wide range of minimally invasive and non-invasive products for aesthetic and hair restoration [4] - The company operates in over 60 countries and has 9 direct markets, showcasing its extensive reach in the industry [4] - Venus Concept's product portfolio includes various aesthetic device platforms and hair restoration systems, such as NeoGraft® and the ARTAS iX® Robotic Hair Restoration system [4] Financial Results Announcement - The company will release its second quarter fiscal year 2025 financial results after market close on August 14, 2025 [1] - A conference call will be held at 5:00 p.m. Eastern Time on the same day to discuss the results and answer questions [2] - For those unable to attend, a replay of the call will be available for two weeks, and a webcast will be archived on the company's investor relations website [3] Investor Relations - Investor relations contact for Venus Concept is managed by ICR Healthcare, with Mike Piccinino, CFA, as the point of contact [5]

Core Viewpoint - Venus Concept Inc. has successfully closed a registered direct offering, raising approximately $1.15 million, with potential additional proceeds of up to $2.3 million from unregistered short-term warrants [1][3]. Group 1: Offering Details - The company sold 434,720 shares of common stock at a price of $2.65 per share [1]. - Concurrently, unregistered short-term warrants were issued to purchase up to 869,440 shares at the same exercise price, which are immediately exercisable and will expire in eighteen months [1][3]. - The gross proceeds from the offering are approximately $1.15 million before fees and expenses [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for general corporate purposes [3]. Group 3: Company Overview - Venus Concept is a global leader in medical aesthetic technology, offering a wide range of minimally invasive and non-invasive products across over 60 countries [7]. - The product portfolio includes various aesthetic device platforms and hair restoration systems, supported by prominent healthcare growth equity investors [7].